PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
June 5, 20240 citationsOpen Access

FIGURE 1 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models

View Full Paper
ZGZhanfang GuoJLJingqin LuoRMR. Jay Mashl

Key Points

Key points are not available for this paper at this time.

Abstract

PI3K pathway alterations of selected TNBC PDX models. A, Molecular characteristics of the eight TNBC PDX models included in this study, including mutation status of candidate genes based on whole exome sequencing, breast cancer intrinsic subtype and TNBC subtype derived from gene expression profiling, and PI3K pathway signaling activity indicated by levels of AKT phosphorylation and PTEN by RPPA analysis for each model. B, Representative pictures of PTEN IHC, demonstrating loss of PTEN expression in four of the eight PDX models. The number at the right lower corner of each IHC picture refers to the WHIM ID of the PDX model analyzed. Note the positive PTEN staining of the stromal cells, which serves as an internal control.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Guo et al. (2024) studied this question.

synapsesocial.com/papers/68e660cfb6db6435875eed65https://doi.org/10.1158/2767-9764.25976534
Ask AI
Helpful
Bookmark
Share
View Full Paper

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Supplementary Figure S3 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models2024
  2. 2Supplementary Figure S3 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models2024
  3. 3Supplementary Figure S1 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models2024
  4. 4Supplementary Figure S1 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models2024
  5. 5Supplementary Figure S4 from Evaluation of Copanlisib in Combination with Eribulin in Triple-negative Breast Cancer Patient-derived Xenograft Models2024